Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets? (2020)
- Authors:
- USP affiliated authors: VALERA, ELVIS TERCI - FMRP ; ANNICHINI, MARIA SOL BRASSESCO - FFCLRP ; CUNHA, RENATO LUIZ GUERINO - FMRP ; ELIAS JÚNIOR, JORGE - FMRP ; TONE, LUIZ GONZAGA - FMRP
- Unidades: FMRP; FFCLRP
- DOI: 10.1080/08880018.2020.1811438
- Subjects: ANTICORPOS MONOCLONAIS; HISTIOCITOSE; NEOPLASIAS POR TIPO HISTOLÓGICO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Pediatric Hematology and Oncology
- ISSN: 0888-0018
- Volume/Número/Paginação/Ano: v. 38, n. 1, p. 89-96, 2020
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
VALERA, Elvis Terci et al. Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets?. Pediatric Hematology and Oncology. Abingdon: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1080/08880018.2020.1811438. Acesso em: 23 abr. 2024. , 2020 -
APA
Valera, E. T., Brassesco, M. S., Reis, M. B. F. dos, Maggioni, G., Guerino-Cunha, R. L., Grecco, C. E., et al. (2020). Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets? Pediatric Hematology and Oncology. Abingdon: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1080/08880018.2020.1811438 -
NLM
Valera ET, Brassesco MS, Reis MBF dos, Maggioni G, Guerino-Cunha RL, Grecco CE, Elias Júnior J, Kato M, Tone LG. Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets? [Internet]. Pediatric Hematology and Oncology. 2020 ; 38( 1): 89-96.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1080/08880018.2020.1811438 -
Vancouver
Valera ET, Brassesco MS, Reis MBF dos, Maggioni G, Guerino-Cunha RL, Grecco CE, Elias Júnior J, Kato M, Tone LG. Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child. [Carta]: Is it time to consider new targets? [Internet]. Pediatric Hematology and Oncology. 2020 ; 38( 1): 89-96.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1080/08880018.2020.1811438 - Interplay between the RNA binding‐protein Musashi and developmental signaling pathways
- Electromagnetic fields at extremely low frequencies and the risk for childhood leukemia [Editorial]: do we have enough information to warrant this association?
- Anticancer activity of 7-epiclusianone, a benzophenone from Garcinia brasiliensis, in glioblastoma
- A foretaste for pediatric glioblastoma therapy: targeting the NF-kB pathway with DHMEQ
- The antiproliferative and pro-apoptotic effects of methoxyamine on pediatric medulloblastoma cell lines exposed to ionizing radiation and chemotherapy
- TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia
- Base excision repair inhibition by methoxyamine impairs growth and sensitizes osteosarcoma cells to conventional treatments
- Bl 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments
- Mowat-Wilson syndrome: growth charts
- CRISPR toolbox: a versatilidade da técnica
Informações sobre o DOI: 10.1080/08880018.2020.1811438 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | 003037648.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
